These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 32085669)
1. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. Di Cosimo S; Appierto V; Pizzamiglio S; Silvestri M; Baselga J; Piccart M; Huober J; Izquierdo M; de la Pena L; Hilbers FS; de Azambuja E; Untch M; Pusztai L; Pritchard K; Nuciforo P; Vincent-Salomon A; Symmans F; Apolone G; de Braud FG; Iorio MV; Verderio P; Daidone MG Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085669 [TBL] [Abstract][Full Text] [Related]
2. Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO. Pizzamiglio S; Ciniselli CM; de Azambuja E; Agbor-Tarh D; Moreno-Aspitia A; Suter TM; Trama A; De Santis MC; De Cecco L; Iorio MV; Silvestri M; Pruneri G; Verderio P; Di Cosimo S Breast Cancer Res Treat; 2024 Jul; 206(2):285-294. PubMed ID: 38689174 [TBL] [Abstract][Full Text] [Related]
3. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. Di Cosimo S; Appierto V; Pizzamiglio S; Tiberio P; Iorio MV; Hilbers F; de Azambuja E; de la Peña L; Izquierdo M; Huober J; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Daidone MG Clin Cancer Res; 2019 Jul; 25(13):3887-3895. PubMed ID: 30814109 [TBL] [Abstract][Full Text] [Related]
4. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Pizzamiglio S; Cosentino G; Ciniselli CM; De Cecco L; Cataldo A; Plantamura I; Triulzi T; El-Abed S; Wang Y; Bajji M; Nuciforo P; Huober J; Ellard SL; Rimm DL; Gombos A; Daidone MG; Verderio P; Tagliabue E; Di Cosimo S; Iorio MV Cancer Med; 2022 Jan; 11(2):332-339. PubMed ID: 34921525 [TBL] [Abstract][Full Text] [Related]
5. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer. Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030 [TBL] [Abstract][Full Text] [Related]
7. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance. Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337 [TBL] [Abstract][Full Text] [Related]
8. Plasma-based microRNA signatures in early diagnosis of breast cancer. Li X; Zou W; Wang Y; Liao Z; Li L; Zhai Y; Zhang L; Gu S; Zhao X Mol Genet Genomic Med; 2020 May; 8(5):e1092. PubMed ID: 32124558 [TBL] [Abstract][Full Text] [Related]
9. Plasma microRNA-195, -34c, and - 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients. Rezaei Z; Dastjerdi K; Allahyari A; ShahidSales S; Talebian S; Maharati A; Zangooie A; Zangouei AS; Sadri F; Sargazi S Toxicol Appl Pharmacol; 2023 Sep; 475():116652. PubMed ID: 37557922 [TBL] [Abstract][Full Text] [Related]
10. The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer. Othman MS; Elabbasy MT; Aref AM; Altaleb AA; Mohammed MH; Soliman DAM; El-Khazragy N Technol Cancer Res Treat; 2024; 23():15330338241292226. PubMed ID: 39429192 [No Abstract] [Full Text] [Related]
11. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252 [TBL] [Abstract][Full Text] [Related]
12. MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients. Lote H; Mousoullou F; Vlachogiannis G; Lampis A; Satchwell L; Peckitt C; Fong C; Begum R; Kidd S; Cromarty S; Gordon A; Fribbens C; Rao S; Starling N; Chau I; Cunningham D; Valeri N Front Oncol; 2023; 13():1258365. PubMed ID: 38094609 [TBL] [Abstract][Full Text] [Related]
13. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Li H; Liu J; Chen J; Wang H; Yang L; Chen F; Fan S; Wang J; Shao B; Yin D; Zeng M; Li M; Li J; Su F; Liu Q; Yao H; Su S; Song E Nat Commun; 2018 Apr; 9(1):1614. PubMed ID: 29691399 [TBL] [Abstract][Full Text] [Related]
14. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. Di Cosimo S; Ciniselli CM; Pizzamiglio S; Cappelletti V; Silvestri M; El-Abed S; Izquierdo M; Bajji M; Nuciforo P; Huober J; Cameron D; Chia S; Gomez HL; Iorio MV; Vingiani A; Pruneri G; Verderio P Front Oncol; 2022; 12():1028825. PubMed ID: 36798690 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Serum MicroRNAs (miR-9-5p, miR-17-5p, and miR-148a-3p) as Potential Biomarkers of Breast Cancer. Li X; Tang X; Li K; Lu L Biomed Res Int; 2022; 2022():9961412. PubMed ID: 35111850 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro. Normann LS; Aure MR; Leivonen SK; Haugen MH; Hongisto V; Kristensen VN; Mælandsmo GM; Sahlberg KK Sci Rep; 2021 May; 11(1):10893. PubMed ID: 34035375 [TBL] [Abstract][Full Text] [Related]
17. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. Powles RL; Redmond D; Sotiriou C; Loi S; Fumagalli D; Nuciforo P; Harbeck N; de Azambuja E; Sarp S; Di Cosimo S; Huober J; Baselga J; Piccart-Gebhart M; Elemento O; Pusztai L; Hatzis C JAMA Oncol; 2018 Nov; 4(11):e181564. PubMed ID: 29902299 [TBL] [Abstract][Full Text] [Related]
18. Bioinformatic analysis of peripheral blood miRNA of breast cancer patients in relation with anthracycline cardiotoxicity. Yadi W; Shurui C; Tong Z; Suxian C; Qing T; Dongning H BMC Cardiovasc Disord; 2020 Feb; 20(1):43. PubMed ID: 32013934 [TBL] [Abstract][Full Text] [Related]
19. Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer. Zhang J; Raju GS; Chang DW; Lin SH; Chen Z; Wu X Cancer; 2018 Feb; 124(4):785-796. PubMed ID: 29112225 [TBL] [Abstract][Full Text] [Related]
20. Cytological effects of honokiol treatment and its potential mechanism of action in non-small cell lung cancer. Zhang J; Zhang Y; Shen W; Fu R; Ding Z; Zhen Y; Wan Y Biomed Pharmacother; 2019 Sep; 117():109058. PubMed ID: 31176168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]